# Zimmer Biomet Holdings, Inc.: financial statements, quarterly

ZBH · NYSE · CIK 1136869 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/zbh.md) · [Financials](/companies/zbh/financials.md) · [Filings](/companies/zbh/filings.md) · [Insiders](/companies/zbh/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/zbh/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [1,754](/filings/0000950170-24-118959.md) | [1,940 d](/filings/0001193125-26-059853.md) | [1,889](/filings/0000950170-25-063509.md) | [1,942](/filings/0000950170-25-104989.md) | [1,824](/filings/0001193125-25-266884.md) | [2,023 d](/filings/0001193125-26-059853.md) | [1,909](/filings/0001193125-26-201710.md) | [2,077](/filings/0001193125-26-335044.md) | [2,001](/filings/0001193125-25-266884.md) | [2,244 d](/filings/0001193125-26-059853.md) | [2,087](/filings/0001193125-26-201710.md) | [2,177](/filings/0001193125-26-335044.md) |
| Cost of revenue | $m | [519](/filings/0000950170-24-118959.md) | [539 d](/filings/0001193125-26-059853.md) | [512](/filings/0000950170-25-063509.md) | [554](/filings/0000950170-25-104989.md) | [539](/filings/0001193125-25-266884.md) | [587 d](/filings/0001193125-26-059853.md) | [550](/filings/0001193125-26-201710.md) | [592](/filings/0001193125-26-335044.md) | [559](/filings/0001193125-25-266884.md) | [792 d](/filings/0001193125-26-059853.md) | [576](/filings/0001193125-26-201710.md) | [636](/filings/0001193125-26-335044.md) |
| Gross profit | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Selling, general and administrative | $m | [675](/filings/0000950170-24-118959.md) | [722 d](/filings/0001193125-26-059853.md) | [736](/filings/0000950170-25-063509.md) | [737](/filings/0000950170-25-104989.md) | [710](/filings/0001193125-25-266884.md) | [747 d](/filings/0001193125-26-059853.md) | [759](/filings/0001193125-26-201710.md) | [815](/filings/0001193125-26-335044.md) | [811](/filings/0001193125-25-266884.md) | [872 d](/filings/0001193125-26-059853.md) | [850](/filings/0001193125-26-201710.md) | [899](/filings/0001193125-26-335044.md) |
| Operating income | $m | [267](/filings/0000950170-24-118959.md) | [354 d](/filings/0001193125-26-059853.md) | [266](/filings/0000950170-25-063509.md) | [351](/filings/0000950170-25-104989.md) | [280](/filings/0001193125-25-266884.md) | [389 d](/filings/0001193125-26-059853.md) | [292](/filings/0001193125-26-201710.md) | [300](/filings/0001193125-26-335044.md) | [351](/filings/0001193125-25-266884.md) | [155 d](/filings/0001193125-26-059853.md) | [373](/filings/0001193125-26-201710.md) | [326](/filings/0001193125-26-335044.md) |
| Income tax | $m | [56.4](/filings/0000950170-24-118959.md) | [(135) d](/filings/0001193125-26-059853.md) | [42.3](/filings/0000950170-25-063509.md) | [59.1](/filings/0000950170-25-104989.md) | [(18.9)](/filings/0001193125-25-266884.md) | [48.9 d](/filings/0001193125-26-059853.md) | [46.5](/filings/0001193125-26-201710.md) | [71.2](/filings/0001193125-26-335044.md) | [48.0](/filings/0001193125-25-266884.md) | [(39.9) d](/filings/0001193125-26-059853.md) | [63.0](/filings/0001193125-26-201710.md) | [55.5](/filings/0001193125-26-335044.md) |
| Net income | $m | [163](/filings/0000950170-24-118959.md) | [419 d](/filings/0001193125-26-059853.md) | [172](/filings/0000950170-25-063509.md) | [243](/filings/0000950170-25-104989.md) | [249](/filings/0001193125-25-266884.md) | [240 d](/filings/0001193125-26-059853.md) | [182](/filings/0001193125-26-201710.md) | [153](/filings/0001193125-26-335044.md) | [231](/filings/0001193125-25-266884.md) | [139 d](/filings/0001193125-26-059853.md) | [238](/filings/0001193125-26-201710.md) | [198](/filings/0001193125-26-335044.md) |
| Diluted EPS | $ per share | [0.77](/filings/0000950170-24-118959.md) | not reported | [0.84](/filings/0000950170-25-063509.md) | [1.18](/filings/0000950170-25-104989.md) | [1.23](/filings/0001193125-25-266884.md) | not reported | [0.91](/filings/0001193125-26-201710.md) | [0.77](/filings/0001193125-26-335044.md) | [1.16](/filings/0001193125-25-266884.md) | not reported | [1.22](/filings/0001193125-26-201710.md) | [1.03](/filings/0001193125-26-335044.md) |
| Basic EPS | $ per share | [0.78](/filings/0000950170-24-118959.md) | not reported | [0.84](/filings/0000950170-25-063509.md) | [1.18](/filings/0000950170-25-104989.md) | [1.23](/filings/0001193125-25-266884.md) | not reported | [0.92](/filings/0001193125-26-201710.md) | [0.77](/filings/0001193125-26-335044.md) | [1.17](/filings/0001193125-25-266884.md) | not reported | [1.22](/filings/0001193125-26-201710.md) | [1.03](/filings/0001193125-26-335044.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: not reported
- Research and development: not reported
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $bn | [0.3](/filings/0000950170-23-060232.md) | [0.4](/filings/0000950170-25-026604.md) | [0.4](/filings/0000950170-24-052097.md) | [0.4](/filings/0000950170-24-092746.md) | [0.6](/filings/0000950170-24-118959.md) | [0.5](/filings/0001193125-26-059853.md) | [1.4](/filings/0000950170-25-063509.md) | [0.6](/filings/0000950170-25-104989.md) | [1.3](/filings/0001193125-25-266884.md) | [0.6](/filings/0001193125-26-335044.md) | [0.4](/filings/0001193125-26-201710.md) | [0.4](/filings/0001193125-26-335044.md) |
| Current assets | $bn | [4.4](/filings/0000950170-23-060232.md) | [4.6](/filings/0000950170-25-026604.md) | [4.6](/filings/0000950170-24-052097.md) | [4.6](/filings/0000950170-24-092746.md) | [4.9](/filings/0000950170-24-118959.md) | [4.7](/filings/0001193125-26-059853.md) | [5.6](/filings/0000950170-25-063509.md) | [5.1](/filings/0000950170-25-104989.md) | [5.8](/filings/0001193125-25-266884.md) | [5.1](/filings/0001193125-26-335044.md) | [5.0](/filings/0001193125-26-201710.md) | [5.1](/filings/0001193125-26-335044.md) |
| Total assets | $bn | [21.2](/filings/0000950170-23-060232.md) | [21.5](/filings/0000950170-25-026604.md) | [21.5](/filings/0000950170-24-052097.md) | [21.5](/filings/0000950170-24-092746.md) | [21.7](/filings/0000950170-24-118959.md) | [21.4](/filings/0001193125-26-059853.md) | [22.2](/filings/0000950170-25-063509.md) | [22.9](/filings/0000950170-25-104989.md) | [23.5](/filings/0001193125-25-266884.md) | [23.1](/filings/0001193125-26-335044.md) | [22.7](/filings/0001193125-26-201710.md) | [22.8](/filings/0001193125-26-335044.md) |
| Current liabilities | $bn | [2.1](/filings/0000950170-23-060232.md) | [2.9](/filings/0000950170-25-026604.md) | [2.8](/filings/0000950170-24-052097.md) | [3.6](/filings/0000950170-24-092746.md) | [3.6](/filings/0000950170-24-118959.md) | [2.5](/filings/0001193125-26-059853.md) | [2.3](/filings/0000950170-25-063509.md) | [2.7](/filings/0000950170-25-104989.md) | [2.4](/filings/0001193125-25-266884.md) | [2.6](/filings/0001193125-26-335044.md) | [2.9](/filings/0001193125-26-201710.md) | [3.0](/filings/0001193125-26-335044.md) |
| Total liabilities | $bn | [8.7](/filings/0000950170-23-060232.md) | [9.0](/filings/0000950170-25-026604.md) | [8.8](/filings/0000950170-24-052097.md) | [8.8](/filings/0000950170-24-092746.md) | [9.3](/filings/0000950170-24-118959.md) | [8.9](/filings/0001193125-26-059853.md) | [9.8](/filings/0000950170-25-063509.md) | [10.3](/filings/0000950170-25-104989.md) | [10.7](/filings/0001193125-25-266884.md) | [10.4](/filings/0001193125-26-335044.md) | [10.0](/filings/0001193125-26-201710.md) | [10.2](/filings/0001193125-26-335044.md) |
| Long-term debt | $bn | [5.1](/filings/0000950170-23-060232.md) | [4.9](/filings/0000950170-25-026604.md) | [4.8](/filings/0000950170-24-052097.md) | [4.0](/filings/0000950170-24-092746.md) | [4.7](/filings/0000950170-24-118959.md) | [5.3](/filings/0001193125-26-059853.md) | [6.6](/filings/0000950170-25-063509.md) | [6.8](/filings/0000950170-25-104989.md) | [7.5](/filings/0001193125-25-266884.md) | [6.9](/filings/0001193125-26-335044.md) | [6.3](/filings/0001193125-26-201710.md) | [6.3](/filings/0001193125-26-335044.md) |
| Current portion of debt | $bn | [0.4](/filings/0000950170-23-060232.md) | [0.9](/filings/0000950170-25-026604.md) | [1.0](/filings/0000950170-24-052097.md) | [1.9](/filings/0000950170-24-092746.md) | [1.7](/filings/0000950170-24-118959.md) | [0.9](/filings/0001193125-26-059853.md) | [0.6](/filings/0000950170-25-063509.md) | [0.8](/filings/0000950170-25-104989.md) | [0.6](/filings/0001193125-25-266884.md) | [0.6](/filings/0001193125-26-335044.md) | [1.2](/filings/0001193125-26-201710.md) | [1.2](/filings/0001193125-26-335044.md) |
| Short-term borrowings | $bn | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $bn | [12.5](/filings/0000950170-23-060232.md) | [12.5](/filings/0000950170-25-026604.md) | [12.6](/filings/0000950170-24-052097.md) | [12.7](/filings/0000950170-24-092746.md) | [12.4](/filings/0000950170-24-118959.md) | [12.5](/filings/0001193125-26-059853.md) | [12.4](/filings/0000950170-25-063509.md) | [12.5](/filings/0000950170-25-104989.md) | [12.8](/filings/0001193125-25-266884.md) | [12.7](/filings/0001193125-26-335044.md) | [12.7](/filings/0001193125-26-201710.md) | [12.6](/filings/0001193125-26-335044.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Short-term borrowings: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [338 d](/filings/0000950170-24-118959.md) | [588 d](/filings/0001193125-26-059853.md) | [228](/filings/0000950170-25-063509.md) | [369 d](/filings/0000950170-25-104989.md) | [396 d](/filings/0001193125-25-266884.md) | [506 d](/filings/0001193125-26-059853.md) | [383](/filings/0001193125-26-201710.md) | [378 d](/filings/0001193125-26-335044.md) | [419 d](/filings/0001193125-25-266884.md) | [517 d](/filings/0001193125-26-059853.md) | [359](/filings/0001193125-26-201710.md) | [448 d](/filings/0001193125-26-335044.md) |
| Capital expenditure | $m | [84.3 d](/filings/0000950170-24-118959.md) | [62.8 d](/filings/0001193125-26-059853.md) | [55.1](/filings/0000950170-25-063509.md) | [52.7 d](/filings/0000950170-25-104989.md) | [44.5 d](/filings/0001193125-25-266884.md) | [51.5 d](/filings/0001193125-26-059853.md) | [44.6](/filings/0001193125-26-201710.md) | [50.1 d](/filings/0001193125-26-335044.md) | [55.0 d](/filings/0001193125-25-266884.md) | [74.8 d](/filings/0001193125-26-059853.md) | [36.3](/filings/0001193125-26-201710.md) | [54.2 d](/filings/0001193125-26-335044.md) |
| Dividends paid | $m | [50.1 d](/filings/0000950170-24-118959.md) | [50.2 d](/filings/0001193125-26-059853.md) | [49.4](/filings/0000950170-25-063509.md) | [49.4 d](/filings/0000950170-25-104989.md) | [49.2 d](/filings/0001193125-25-266884.md) | [48.0 d](/filings/0001193125-26-059853.md) | [47.8](/filings/0001193125-26-201710.md) | [47.5 d](/filings/0001193125-26-335044.md) | [47.5 d](/filings/0001193125-25-266884.md) | [47.5 d](/filings/0001193125-26-059853.md) | [46.9](/filings/0001193125-26-201710.md) | [46.5 d](/filings/0001193125-26-335044.md) |
| Share repurchases | $m | [0.0 d](/filings/0000950170-24-118959.md) | [410 d](/filings/0001193125-26-059853.md) | [114](/filings/0000950170-25-063509.md) | [85.9 d](/filings/0000950170-25-104989.md) | [596 d](/filings/0001193125-25-266884.md) | [72.2 d](/filings/0001193125-26-059853.md) | [230](/filings/0001193125-26-201710.md) | [7.2 d](/filings/0001193125-26-335044.md) | [0.0 d](/filings/0001193125-25-266884.md) | [250 d](/filings/0001193125-26-059853.md) | [250](/filings/0001193125-26-201710.md) | [251 d](/filings/0001193125-26-335044.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Dividends paid: us-gaap:PaymentsOfDividendsCommonStock
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [210](/filings/0000950170-23-060232.md) | [210](/filings/0000950170-24-052097.md) | [210](/filings/0000950170-24-092746.md) | [210](/filings/0000950170-24-118959.md) | [206](/filings/0000950170-25-063509.md) | [206](/filings/0000950170-25-104989.md) | [203](/filings/0001193125-25-266884.md) | [200](/filings/0001193125-26-201710.md) | [198](/filings/0001193125-26-335044.md) | [199](/filings/0001193125-25-266884.md) | [196](/filings/0001193125-26-201710.md) | [193](/filings/0001193125-26-335044.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 190,737,689 at 2026-07-30, from the cover of the [10-Q filed 2026-08-05](/filings/0001193125-26-335044.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:34 ET. No prices; not investment advice.